Title:
A randomized, open-label Phase III efficacy and safety study of Atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340) The DANTE Trial
Phase:
III
Contact:
Beatrice Stranz / Study Nurse
Email-Address:
Beatrice.Stranz@med.uni-heidelberg.de
Clinical Investigator:
Prof. Dr. med. Georg Martin Haag
Registration:
Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe
NCT03421288
EudraCT-Number:
Siehe EU klinisches Studienregister
2017-001979-23